Ajinomoto Bio-Pharma Services Awarded Three 'CDMO Leadership Awards'
PR99764
SAN DIEGO and TOKYO and WETTEREN, Belgium, March 14, 2023 /PRNewswire=KYODO JBN/ --
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of
biopharmaceutical contract development and manufacturing services, received
three CDMO Leadership Awards in the categories Capabilities, Compatibility, and
Expertise in both the Overall and Big Pharma respondent groups.
Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg
Established in 2011, the CDMO Leadership Awards recognize top outsourcing
partners. The awards, rebranded from the CMO Leadership Awards, are presented
by Life Science Leader magazine and Industry Standard Research. 72 contract
manufacturers were assessed by 23 performance metrics in ISR's annual Contract
Manufacturing Quality Benchmarking survey. Respondents only evaluate companies
with which they have worked on an outsourced project within the past 18 months.
Based on ratings of these recent outsourced projects provided by sponsors, this
experiential feedback is analyzed by sponsor company size to reveal leading
CDMOs in different performance categories.
"For over a decade, these awards have been the most meaningful for biopharma
organizations striving to obtain optimal outcomes from their outsourcing
activities. Our research arm, ISR Reports, which only surveys drug sponsors who
have worked directly and recently with specific CDMOs, ensures the validity of
these results. Our winners are your gold-medalists of outsourcing." Louis
Garguilo, Chief Editor and Conference Chair, Outsourced Pharma.
"We are proud to be recognized by our partners as we continue to invest in new
technologies, quality systems, and facilities to increase our capabilities and
expertise to meet the needs of our clients. We take pride in knowing our
efforts are helping countless patients for years to come." Said Yasuyuki Otake,
General Manager, Bio-Pharma Services Department.
About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and
manufacturing organization with sites in Belgium, United States, Japan, and
India, providing comprehensive development, cGMP manufacturing, and aseptic
fill finish services for small and large molecule APIs and intermediates.
Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and
capabilities for pre-clinical and pilot programs to commercial quantities,
including Corynex(R) protein expression technology, oligonucleotide synthesis,
antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis,
continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is
dedicated to providing a high level of quality and service to meet our client's
needs. Learn more: www.AjiBio-Pharma.com
SOURCE: Ajinomoto Bio-Pharma Services
CONTACT: info@us.ajibio-pharma.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。